DRI Healthcare Trust T.DHT.UN

RE:RFK Jr

[SONOFFERGUS]

Biotech/pharma getting smashed.  DRI says that is probably a good thing for royalty cos.  RPRX up.

From Q3 Q&A:

Justin Keywood — Stifel Good morning. Thanks for taking my call. Just had a question. With the new US administration coming in, do you anticipate any impact directionally on the portfolio of assets or new pursuits? Any puts or takes to note?

Ali Hedayat It’s too early. Sorry

Navin Jacob 29 Yeah, I was going to say the exact same thing. I think we just have to see, Justin. What exactly the platform is for the new administration is a bit of a question as it relates to healthcare. There have been some various names that have been thrown around that are associated with the new administration that may have a very different view of how the biopharmaceutical space and drugs should be approved and which drugs should be approved. All of that is not necessarily a bad thing, quite frankly, for our business. I think it adds that, plus any potential for inflation, which most macroeconomists believe will occur under the new administration and will translate into higher interest rates. All of that is, quite frankly, not a negative thing, probably exactly the opposite, actually, for our industry, i.e., the royalty industry, insofar as volatility in or lack of understanding of pricing and/or higher interest rates makes for challenging equity capital markets for the biotech sector, which should be very positive for the royalty investing sector.